[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"WestVac Biopharma Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":135},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,70,97,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640827","phase-1-wsk-im02-in-advanced-solid-tumors-with-malignant-effusions-phase-i-100640827",false,"NCT07615894","WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)","A Single-Arm, Open-Label, Prospective Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of WSK-IM02 in Patients With Advanced Solid Tumors Complicated by Malignant Pleural or Peritoneal Effusions","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years.\n2. Voluntarily sign informed consent form.\n3. Patients with histologically or cytologically confirmed advanced solid tumors.\n4. Histologically or cytologically confirmed malignant pleural\u002Fperitoneal effusion requiring drainage; or, in the absence of histologic\u002Fcytologic evidence, pleural effusion with clear imaging evidence of malignant pleural\u002Fperitoneal lesions on chest\u002Fabdominal CT and diagnosed as malignant pleural\u002Fperitoneal tumor in clinical practice.\n5. Have received standard systemic therapy and developed clinical symptoms of serous cavity metastasis.\n6. ECOG performance status: 0-2 points. Patients with ECOG 3 may be included if, in the investigator's judgment, removal of the effusion could improve the score to 2 or above.\n7. Life expectancy ≥3 months.\n8. Adequate major organ function.\n9. Able to tolerate thoracentesis\u002Fabdominocentesis and catheter placement, or already have a functional thoracic\u002Fabdominal drainage catheter in place, and agree to receive study drug treatment via this route.\n\nExclusion Criteria:\n\n1. Participation in any other interventional clinical trial within 4 weeks prior to the first dose of study drug.\n2. Received local intracavitary therapy for pleural\u002Fperitoneal effusion (excluding diagnostic or symptom-relieving puncture\u002Fdrainage) within 2 weeks prior to the first dose of study drug.\n3. Received extra-thoracic\u002Fextra-abdominal radiotherapy within 2 weeks prior to the first dose of study drug, or received radical radiotherapy to pleural\u002Fperitoneal or pulmonary\u002Fabdominal lesions within 8 weeks prior to enrollment (palliative radiotherapy to chest\u002Fabdomen is permitted).\n4. Underwent major thoracic or abdominal surgery within 4 weeks prior to the first dose of study drug and not fully recovered, or planned to undergo elective major surgery during the study period.\n5. Any toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1 at the start of study treatment.\n6. Symptomatic, uncontrolled central nervous system (CNS) metastases or leptomeningeal metastases that, in the investigator's judgment, make the patient unsuitable for enrollment.\n7. Known human immunodeficiency virus (HIV) infection, active hepatitis B, active hepatitis C, or active syphilis infection.\n8. Active, uncontrolled infection requiring systemic antibiotics, antivirals, or antifungal therapy.\n9. Pregnant or breastfeeding women.\n10. Definite history of severe mental or cognitive disorders that, in the investigator's opinion, may affect study compliance or safety assessment.\n11. Presence of any active autoimmune disease, or history of autoimmune disease requiring systemic immunosuppressive therapy (topical glucocorticoids or inhaled\u002Fintra-articular steroids are permitted).\n12. Require systemic corticosteroids or other immunosuppressants within 2 weeks prior to the first dose of study drug, and expected to require long-term use during the study.\n13. Have poorly controlled or severe cardiovascular disease.\n14. Have poorly controlled metabolic disease or complete\u002Fsevere gastrointestinal obstruction requiring intervention.\n15. Hypersensitivity to the investigational drug, any of its excipients, liposomal formulations, or kanamycin.\n16. Have had a major thromboembolic event within 6 months prior to the first dose, or have a clear bleeding tendency.\n17. Active local infection at the administration site.\n18. Uncorrectable coagulation dysfunction that would pose a high risk for thoracentesis\u002Fabdominocentesis or catheter placement.\n19. Have any other concurrent, serious, and\u002For uncontrolled medical condition.","ALL","18 Years","75 Years",{"count":20,"type":21},9,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural\u002Fintraperitoneal infusion of WSK-IM02 in patients with advanced solid tumors complicated by malignant pleural or peritoneal effusions who have failed standard of care.",[27,28,29],"Advanced Solid Tumors","Malignant Pleural Effusions","Malignant Ascites","NOT_YET_RECRUITING","2026-05-22",{"date":33,"type":34},"2026-05-29","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2029-06-30",{"name":40,"class":41},"WestVac Biopharma Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100628502","phase-1-a-phase-1-clinical-study-to-evaluate-the-safety-and-efficacy-of-wsk-im02-in-patients-with-platinum-resistant-recurrent-ovarian-cancer-100628502","NCT07462468","A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.","A Phase 1, Single-arm, Single-center, Open-label, Prospective Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.","Inclusion Criteria:\n\n1. Female, age ≥18 years old, ≤ 75 years old.\n2. Willing to voluntarily sign the informed consent form.\n3. Patients must have histopathologically confirmed ovarian cancer, with no requirement for additional tumor tissue biopsy during the screening period.\n4. Platinum-resistant recurrent ovarian cancer, with an initial response to ≥4 cycles of platinum-based therapy, followed by confirmed disease recurrence or progression 28 days to 6 months after the last platinum-containing regimen. At least one subsequent systemic therapy for recurrence\u002Fprogression following platinum resistance, with ≤3 prior lines of systemic therapy (neoadjuvant + adjuvant chemotherapy\u002Fadjuvant chemotherapy counts as one chemotherapy line. Other maintenance therapies may be excluded upon investigator and sponsor 's agreement.\n5. ECOG performance status: 0 - 2.\n6. Life expectancy ≥3 months.\n7. Adequate major organ function within 14 days prior to treatment : Hematology (without transfusion or hematopoietic growth factor support within 14 days): NEUT ≥1.5×10⁹\u002FL, PLT ≥100×10⁹\u002FL, Hb ≥80 g\u002FL. Liver function: ALT ≤2.5 × ULN, AST ≤2.5 × ULN. In the presence of liver metastases, ALT and AST ≤5 × ULN. Renal function: Cr ≤1.5 × ULN or Ccr \\>50 mL\u002Fmin. Coagulation function: APTT ≤1.5 × ULN, INR ≤1.5 × ULN.\n8. At least one measurable lesion per RECIST v1.1 criteria.\n9. Female subjects of childbearing potential must agree to use effective contraceptive methods from signing ICF until at least 6 months after the last dose of the investigational product.\n\nExclusion Criteria:\n\n1. Participation in another investigational drug trial within 4 weeks before enrollment.\n2. Non-epithelial ovarian cancer.\n3. Prior antineoplastic therapy (including chemotherapy, radiotherapy, targeted therapy, hormonal therapy, biologic therapy, immunotherapy, herbal medicine for antineoplastic purposes, or other investigational agents) within 28 days or 5 half-lives (whichever shorter) prior to first dose.\n4. Prior radiotherapy within 4 weeks prior to the first dose (including radiotherapy to \\>25% of bone marrow), or palliative localized radiotherapy to bone metastases within 2 weeks.\n5. Major surgery within 4 weeks prior to the first dose without complete recovery, or elective surgery planned during the trial.\n6. Other malignancies within the past 5 years (except stable breast cancer; except for adequately treated non-melanoma skin cancer or other solid tumors with no evidence of disease for \\>5 years).\n7. Any toxicity from prior therapy that has not recovered to baseline or to ≤ Grade 1 per NCI-CTCAE v6.0 prior to study treatment (except those posing no safety risk per investigator, e.g., alopecia).\n8. Symptomatic CNS or leptomeningeal metastases, or other evidence of uncontrolled CNS or leptomeningeal metastases, and deemed inappropriate for enrollment by investigator.\n9. HIV positive, HbsAg positive with HBV DNA \\> ULN (enrollment allowed if reduced to normal post-antiviral), Anti-HCV positive with HCV RNA positive, Tp-Ab positive.\n10. Active infection requiring systemic anti-infective therapy (per investigator).\n11. Pregnant or breastfeeding.\n12. Known history of drug\u002Falcohol\u002Fsubstance abuse, definite prior history of neurological or psychiatric disorders.\n13. Presence of any active autoimmune disease, history of autoimmune disease or acquired immunodeficiency syndrome.\n14. Corticosteroids (\\>10 mg\u002Fday prednisone equivalent) or other immunosuppressants within 4 weeks prior to study drug, or requiring long-term systemic steroids during study (topical steroids allowed).\n15. Uncontrolled or significant cardiovascular disease, including severe\u002Funstable angina pectoris, symptomatic congestive heart failure (NYHA II-IV), clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, or myocardial infarction within 6 months prior to the first dose.\n16. Poorly controlled hypertension despite antihypertensive therapy (i.e., SBP ≥150 mmHg and\u002For DBP ≥100 mmHg).\n17. Uncontrolled diabetes (defined as HbA1c ≥8%, or 7% ≤ HbA1c \\\u003C8% with clinical symptoms of diabetes, such as polyuria, polydipsia, polyphagia, and weight loss) or other metabolic disorders, severe gastrointestinal bleeding, severe diarrhea (CTCAE ≥ Grade 2), or severe gastrointestinal obstruction requiring intervention.\n18. Pulmonary disease defined as ≥ Grade 3 per NCI-CTCAE v6.0, including dyspnea at rest, requirement for continuous oxygen therapy, or history of ILD.\n19. Known allergy to the investigational product or its major excipients, or kanamycin.\n20. History of thromboembolism, cerebral infarction, hemorrhagic disorders, or evidence of bleeding tendency within 6 months prior to the first dose.\n21. Any other concurrent severe and\u002For uncontrolled medical condition that, in the investigator's judgment, renders the patient unsuitable for participation.\n22. Female patients of childbearing potential unwilling to use effective contraception during the trial and for 6 months post-treatment. Pregnancy test required for patients with amenorrhea on antineoplastics, even if \\>12 months.\n23. Intestinal stoma or obstruction.\n24. Abdominal adhesions or infection precluding intraperitoneal drug administration.\n25. Physical condition unsuitable for intraperitoneal injection or other factors precluding study completion per investigator.","FEMALE",{"count":52,"type":21},36,[24],"A Phase 1, single-arm, single-center, open-label, prospective, dose-escalation, and cohort expansion study to assess the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of WSK-IM02 administered as a single agent to patients with platinum-resistant recurrent ovarian cancer.",[56],"Platinum-resistant Recurrent Ovarian Cancer (PROC)",[58,59,60,61,62],"Ovarian cancer","Platinum-resistant recurrent ovarian cancer (PROC)","cancer","Platinum-resistant","Recurrent ovarian cancer","2026-03-10",{"date":65,"type":34},"2026-03-13",{"date":63,"type":21},{"date":68,"type":21},"2027-09-30",{"name":40,"class":41},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100606073","phase-2-a-phase-2b-clinical-study-of-jdb0131-benzenesulfonate-tablets-100606073","NCT07170800","A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets With Delamanid in Patients With Rifampin-resistant Tuberculosis (JD-RISE)","Inclusion Criteria:\n\n* Age: 14 years through 65 years of age, male or female\n* Weight: 40kg ≤ weight ≤ 90kg\n* Patients with clinically confirmed pulmonary tuberculosis, Drug Susceptibility Testing (DST) results confirmed to be at least rifampicin-resistant, molecular or phenotypic DST results within 3 months before enrollment can be received\n* Sputum acid-fast bacilli smear is positive (≥2+ once or 1+ twice at least)\n* Patients who are currently taking anti-tuberculosis treatment or using drugs with anti-tuberculosis effects agree to stop all anti-tuberculosis drug treatment and complete a 7-day washout period\n* Women of reproductive age must agree to use highly effective contraceptive measures throughout the study and for at least 6 months after discontinuation of the drug. Male participants whose partners are women of reproductive age must agree to use appropriate contraceptive methods throughout the study and for at least 6 months after discontinuation of the drug (see protocol Appendix 1)\n* Fully understand the purpose and requirements of this trial, voluntarily sign the written informed consent and agree to abide by the relevant provisions of the informed consent\n\nExclusion Criteria:\n\n* Those who cannot take delamanid, bedaquiline, or linezolid for various reasons\n* Take delamanid, bedaquiline, or linezolid for more than 1 month (can be enrolled if evidence of no resistance to the above drugs is provided)\n* Hematogenously disseminated pulmonary tuberculosis or severe extrapulmonary tuberculosis as determined by the investigator; or patients with pulmonary tuberculosis who are assessed by the investigator to be likely to require surgical treatment within 8 weeks\n* History of torsades de pointes or risk factors, including a personal or family history of long QT syndrome (LQTS), persistent hypothyroidism, or bradycardia\n* Anyone with any of the following cardiovascular diseases or other conditions within 6 months before enrollment:\n\n  1. Myocardial infarction;\n  2. Heart surgery or coronary revascularization (coronary artery bypass grafting\u002Fpercutaneous transluminal coronary angioplasty);\n  3. Unstable angina;\n  4. Congestive heart failure (New York Heart Association functional class III or IV);\n  5. Transient ischemic attack or severe cerebrovascular disease.\n* Peripheral neuropathy CTCAE grade 3 or 4; Grade 1 or 2 peripheral neuropathy that the investigator judges may progress\u002Fworsen during the study; Patients with optic neuritis\n* History of gastrointestinal surgery or resection that may affect the absorption and\u002For excretion of oral medications\n* Patients who are considered by the investigator to be unsuitable for this trial due to unstable or severe cardiovascular, renal, hepatic, blood, tumor, endocrine metabolic, psychiatric or rheumatic diseases\n* History of alcohol dependence or drug abuse within 6 months before screening, the investigator believes that it may affect the safety of the participants and affect the trial compliance\n* Patients who have used other clinical trial investigational drugs within 3 months before administration\n* Concomitant take drugs that cause bone marrow suppression\n* Concomitant take serotonin reuptake inhibitors, tricyclic antidepressants, serotonin, serotonin receptor agonists, and other drugs\n* Concomitant take drugs that prolong the QT interval, such as quinidine, procainamide, amiodarone, sotalol, etc.\n* Chronic systemic corticosteroid therapy, cumulative take for more than 4 weeks within 3 months before enrollment\n* Allergic to any investigational drug or related substance as confirmed by the researcher's clinical judgment\n* Women who have a positive pregnancy test during screening or are breastfeeding\n* Patients with hepatitis B virus (HBV) positive results (HBsAg, HBeAg, and HBcAb); positive hepatitis C virus (HCV) antibodies and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels \\>3 times the upper limit of normal; positive Human Immunodeficiency Virus (HIV) antibody test; positive syphilis antibody test and active syphilis\n* Laboratory tests show any of the following:\n\n  1. Hemoglobin \\\u003C 80 g\u002FL;\n  2. platelets \\\u003C 75 ✕ 109 \u002FL;\n  3. Aspartate aminotransferase (AST) \\> 3 times the upper limit of normal;\n  4. Alanine aminotransferase (ALT) \\> 3 times the upper limit of normal;\n  5. Serum total bilirubin (TBIL) \\> 2 times the upper limit of normal;\n  6. Serum creatinine (Cr) \\> 1.5 times the upper limit of normal;\n  7. Serum amylase \\> 2 times the upper limit of normal.\n* The following abnormalities were found in the electrocardiogram (ECG):\n\n  1. At least twice QTcF intervals \\> 450 ms (male) or \\> 470 ms (female);\n  2. Pathological Q waves (defined as \\>40 ms or deep \\>0.4-0.5mV);\n  3. ECG suggests preexcitation syndrome;\n  4. ECG suggests left bundle branch block or right bundle branch block; or second or third degree heart block;\n  5. Intraventricular conduction delay with QRS duration \\>120ms;\n  6. Bradycardia with a sinus rate \\\u003C 50 bpm.\n* In the investigator's judgment, any condition that affects the subject's compliance with the study protocol, or any serious medical or psychological condition that may affect the interpretation of efficacy and safety data, or any condition that may affect the subject's safety when participating in the trial","14 Years",{"count":79,"type":21},60,[81],"PHASE2","This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)\u002Fclofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.",[84,85,86],"Tuberculosis","Multidrug Resistant Pulmonary Tuberculosis","Rifampicin-resistant Tuberculosis","RECRUITING","2026-01-27",{"date":90,"type":34},"2026-01-30",{"date":92,"type":34},"2025-09-19",{"date":94,"type":21},"2026-09-04",{"name":40,"class":41},7,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100509256","phase-3-a-phase--clinical-trial-of-recombinant-covid-19-trivalent-xbbba5delta-protein-vaccine-sf9-cell-in-booster-vaccination-100509256","NCT05911061","A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination","A Multicenter, Randomized, Double-Blind, Controlled, Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity in Population Aged 18 Years Old and Above","Inclusion Criteria:\n\n1. Subjects aged 18 years and above, including those with underlying diseases and immunocompromised subjects.\n2. Basic or booster immunization with COVID-19 vaccine ≥6 months.\n3. ≥3 months of SARS-CoV-2 infection history, or never infected.\n4. Have the ability to understand research procedures, with informed consent, voluntarily sign informed consent, and be able to comply with the requirements of clinical research protocols.\n\nExclusion Criteria:\n\n1. Axillary temperature ≥37.3℃.\n2. SARS-CoV-2 antigen or nucleic acid screening positive within the last 48 hours.\n3. Anti-SARS-CoV-2 IgM antibody was positive during the screening period.\n4. It is in the advanced stage of malignant tumor and the disease control is unstable.\n5. Female pregnancy (pregnancy test results are positive), lactation period.\n6. Have serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, heart failure, severe hypertension, and can not be controlled by drugs.\n7. Have other serious chronic conditions such as uncontrolled asthma, diabetes, chronic obstructive pulmonary disease, pulmonary embolism, chronic kidney disease requiring dialysis, cirrhosis of the liver, convulsions, epilepsy and other neurological\u002Fpsychiatric conditions.\n8. Have been diagnosed with congenital or acquired immunodeficiency, HIV infection.\n9. People who are allergic to any component of the investigational vaccine have a history of more severe allergies or allergic reactions to the vaccine in the past.\n10. Congenital or acquired angioedema\u002Fneuroedema.\n11. Asplenia or functional asplenia.\n12. Thrombocytopenia or other clotting disorders (which may cause intramuscular injection contraindications).\n13. Received another investigational drug within 1 month prior to receiving the investigational vaccine.\n14. Received subunit or inactivated vaccine within 14 days prior to receiving the investigational vaccine, or received live attenuated vaccine within 1 month.\n15. Fertile female subjects did not use effective contraception within 1 month prior to enrollment.\n16. Fertile female and male subjects have pregnancy plans and sperm\u002Fegg donation plans from the screening period to 3 months after immunization.\n17. Abnormal laboratory test results during the screening period, which were judged by the researcher to be unsuitable for the study vaccine.\n18. Medical, psychological, social, or other conditions that, in the investigator's judgment, are inconsistent with the protocol or affect the subject's signing of informed consent.",true,{"count":106,"type":21},4950,[108],"PHASE3","A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity",[111],"COVID-19","2024-07-23",{"date":114,"type":34},"2024-07-25",{"date":116,"type":21},"2024-12-30",{"date":118,"type":21},"2025-12-30",{"name":40,"class":41},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":134,"locationsCount":4},"100509255","phase-2-a-clinical-trial-of-recombinant-covid-19-bivalent-xbbprototype-protein-vaccine-sf9-cell-in-booster-vaccination-100509255","NCT05911048","A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination","A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C) in Booster Vaccination in Healthy Population 18 Years Old of Age and Above",{"count":127,"type":21},3100,[81],"A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.",[111],{"date":114,"type":34},{"date":116,"type":21},{"date":118,"type":21},{"name":40,"class":41},""]